BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study Posted byZacks Equity Research January 14, 2022 Leave a comment on BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.